Heart failure: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• SGLT2 29
• GLP-1 6
• TTR 10
• AMPK 0
• NLRP3 0
• NRF2 0
• PI3K 0
• PPAR 0
• AKT 0
• mTOR 0
• HER2 2
• STAT3 0
• TP53 0
• MAPK 0
• SIRT1 0
• STING 0
• EGFR 0
• GIP 4
• HIF-1 0
• PCSK9 0
• DPP-4 0
• VEGF 0
• HMGB1 0
• IL-6 0
• TNF 0
• CTNNB1 0
• YAP 0
• PINK1 0
• ERK 0
• GPX4 0
• JAK 0
• TLR4 0
• IL-1 0
• JNK 0
• MEK 1
• HSP90 0
• DMD 0
• IL-17 0
• MMP-9 0
• PD-1 0
• CD40 0
• COX-2 0
• HDAC 0
• PD-L1 0
• TFEB 0
• ABL1 0
• APOE 0
• AR 0
• BCL-2 0
• FTO 0
• METTL3 0
• MYC 0
• PTEN 0
• ACE2 0
• BDNF 0
• BRAF 0
• BRD4 0
• BTK 0
• CDK4/6 0
• FAK 0

19 of 19+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NINR · F31

  Clarifying symptom experiences and management strategies for breast cancer survivors with cardiotoxicity: A mixed-methods analysis

  University of South Florida· Tampa, United States· US$40,326 awarded in fiscal year 2026· until Jul 2028

• NIH NINR · R01

  Discovery of Symptom Burdens and Their Associations with Health Outcomes among People Living with HIV

  University of Texas Hlth Sci Ctr Houston· Houston, United States· US$402,355 awarded in fiscal year 2026· until Jun 2030

• NIH NINR · R01

  SCH: Integrated AI and Sensing Systems for Mitigating Heart Failure Readmissions in High-Risk Groups with Obesity

  University of Pittsburgh at Pittsburgh· Pittsburgh, United States· US$1,200,000 awarded in fiscal year 2026· until Aug 2030

• NIH NINR · K99

  Leveraging Nurses to Improve Care for Postural Orthostatic Tachycardia Syndrome

  New York University School of Medicine· New York, United States· US$133,547 awarded in fiscal year 2026· until Aug 2028

• NIH NINR · R01

  The Roles, Contributions, and Patient Outcomes Associated with Registered Nurses in Primary Care

  Emory University· Atlanta, United States· US$533,605 awarded in fiscal year 2026· until Jun 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Integrative Modeling of Autonomic dysfunction and Cardiac arrhyThmogenesis (IMpACT)

  Politecnico di Milano· Milano, Italy· EU contribution €193,643· until Aug 2029· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Bioinspired Modulation of Cardiac Troponin I Splicing to Treat Diastolic Dysfunction (TROPOSplice)

  Centro Nacional de Investigaciones Cardiovasculares Carlos Iii (F.s.p.)· Madrid, Spain· EU contribution €1,499,625· until Jan 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  From n=1 to many: Scaling-up gene editing for future heart therapies (ONE2MANY)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Germany· EU contribution €1,499,468· until Dec 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A computational framework for personalising atrial fibrillation treatment to minimise heart failure risk (AFHF-TAILOR)

  Eidgenoessische Technische Hochschule Zuerich· Zuerich, Switzerland· EU contribution €292,119· until Dec 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-CSA

  RAPid TranslatiOnal Research - Heart Failure (RAPTOR-HF)

  Uniwersytet Medyczny Im Piastow Slaskich We Wroclawiu· Wroclaw, Poland· EU contribution €15,000,000· until Dec 2032· 3 countries

10 of 1,993 running projects, newest first. Listed amounts together: US$1.1bn + €318.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  SGLT2-Inhibitors for Sleep Apnea in Heart Failure

  NCT04640493· Columbia University· Updated 13 May 2024

  “Lack of enrollment”Registry text, quoted unchanged. Source

• Terminated

  SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency

  NCT05737186· Peking University People's Hospital· Updated 30 Apr 2024

  “Double blind packaged drug is up to expiration date”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study

  NCT07572032· Kyungsub Song· Source

• Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves

  NCT07610174· Kafrelsheikh University· Source

• Implementation of SGLT-2 Inhibitors in Patients With Heart Failure Through a New Digital Strategy

  NCT05890131· Morten Schou· Source

• SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

  NCT05057806· The University of Texas Health Science Center at San Antonio· Source

• Effects of SGLT2 Inhibitors on Erythropoiesis in Heart Failure

  NCT07478575· University Medical Centre Ljubljana· Source

• Dapagliflozin for Cardio-renal Protection After ICU Discharge

  NCT07025629· Assistance Publique - Hôpitaux de Paris· Source

• Early Gliflozin for Elderly Patients With Acute Decompensated Heart Failure in the Emergency Department

  NCT07392788· Centre Hospitalier Universitaire de Besancon· Source

• Ketones, SGLT2, HFrEF

  NCT06229678· The University of Texas Health Science Center at San Antonio· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 17
• Organoids 5
• Mendelian Randomization Analysis 79
• CRISPR-Cas Systems 7
• Gene Expression Profiling 71
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 10
• Proteomics 108
• Metabolomics 64
• Mass Spectrometry 5
• Flow Cytometry 10
• Immunohistochemistry 13
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 37
• Magnetic Resonance Imaging 155
• Machine Learning 199
• Deep Learning 42
• Cohort Studies 503
• Genome-Wide Association Study 74

• [Multimodality imaging in heart failure: phenotyping and clinical decision-making].

  G Ital Cardiol (Rome), Nov 2026

• [The predictive value of left ventricular strain on cardiac magnetic resonance for adverse events in children and adolescent patients with hypertrophic cardiomyopathy].

  Zhonghua Xin Xue Guan Bing Za Zhi, Oct 2026

• Immune Checkpoint Inhibitor Myocarditis on FDG PET/CT and Cardiac MR.

  Clin Nucl Med, Oct 2026

• [Duchenne muscular dystrophy-associated cardiomyopathy: advances in diagnosis and management].

  Zhongguo Dang Dai Er Ke Za Zhi, Oct 2026

• Left ventricular ejection fraction recovery under contemporary quadruple guideline-directed therapy and the need for ICD/CRT-D implantation in HFrEF: a retrospective single-center cohort study.

  Expert Rev Cardiovasc Ther, Oct 2026

• [Diagnosis of amyloidosis].

  Ther Umsch, Oct 2026

• Myocardial strain evaluation from cardiovascular MRI and CT: physiological principles and clinical perspectives.

  Br J Radiol, Oct 2026

• Glycemic Status, Cardiac Structure, and Function by Magnetic Resonance Imaging: The Jackson Heart Study.

  J Am Heart Assoc, Sept 2026

• Multimodality cardiac imaging in advanced heart failure: Diagnosis, risk stratification, and therapeutic guidance.

  J Int Med Res, Sept 2026

• Cardiac magnetic resonance and fluorodeoxyglucose positron emission tomography/computed tomography imaging phenotypes and their association with outcomes in patients with known or suspected myocarditis.

  J Nucl Cardiol, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.